Jeffrey Jones

Company: CULLINAN THERAPEUTICS, INC.

Job title: Chief Medical Officer

Seminars:

Panel Discussion: Optimizing Patient Treatment Procedure for Best Outcomes

Moderator: Greg Deener, Chief Executive Officer, iCell Gene Therapeutics 2:00 pm

• Discussing regiments for patients such as ideal dosing, timing of certain procedures, and sample collection methods • Evaluating the need for conditioning regiments such as lymphodepletion • How long do patients need to be hospitalized?Read more

day: Day Two Track B, PM

CD19/CD3 Bispecific T-cell Engagers as an Alternative for Safer B-Cell Depletion 2:00 pm

• Discussing clinical results of starting dose efficacy in B-cell lymphoma demonstrating B-cell depletion • Highlighting the application of T-cell engagers to SLE and other autoimmune indicationsRead more

day: Day One Track B, PM